Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 37Colorectal Neoplasms 16Liver Neoplasms 10Biliary Tract Neoplasms 10Cholangiocarcinoma 7Pancreatic Neoplasms 6Adenocarcinoma Of Esophagus 6Stomach Neoplasms 5Diabetes Mellitus, Insulin-Dependent, 12 4Squamous Cell Carcinoma of Head and Neck 3Melanoma 3Esophageal Squamous Cell Carcinoma 3Carcinoma, Non-Small-Cell Lung 3Breast Neoplasms 3Triple Negative Breast Neoplasms 2Small Cell Lung Carcinoma 2Ovarian Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Lung Neoplasms 2Gallbladder Neoplasms 2Esophageal Neoplasms 2Carcinoma, Renal Cell 2Uterine Cervical Neoplasms 1Unresectable Hepatocellular Carcinoma 1Prostatic Neoplasms 1Peritoneal Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Cancer Non-resectable 1Microsatellite Instability 1

Interventions

Propranolol 3Portasystemic Shunt, Transjugular Intrahepatic 2tremelimumab 1durvalumab 1Radiofrequency Ablation 1Liver Transplantation 1Hepatectomy 1Diagnostic Imaging 1Carvedilol 1Bevacizumab 16-acetylaminocaproic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hypertension, Portal × tremelimumab × Gastrointestinal × Clear all
NCT05027425 2026-05-06

Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant

University of Cincinnati

Phase 2 Terminated
8 enrolled 9 charts
Gastrointestinal

Fibrosis, Carcinoma, Hepatocellular, Hypertension, Portal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡